The past two decades have seen an upsurge in detecting the genetic determinants of hypertension. Thereafter, a-adducin gene ranks high and one polymorphism, G460W (rs4961), has attracted special attention. We first performed a case-control study to investigate the association of this polymorphism with essential hypertension among Shanghai residents, and then metaanalyzed all available evidence. A total of 950 subjects were recruited for genetic association study. Genotyping for G460W was conducted using PCR and restriction fragment length polymorphism techniques. Meta-analysis search was limited to articles published in English and studies on humans. Data and study quality were assessed in duplicate. Publication bias was evaluated using the fail-safe number. Our case-control study provided no evidence for the association of G460W with essential hypertension, even under assumptions of three genetic modes of inheritance (P40.05). The subsequent meta-analysis including 15 studies with 4417 cases and 5716 controls also failed to demonstrate overall this association, even upon stratification by race (Caucasians and Asians). For example, the summary odds ratio (OR) under a random effects model indicated that carriers of 460W allele were 1.09 times more likely to develop hypertension (95% confidence interval (CI), 0.96-1.24; P ¼ 0.19) among Asians, whereas a protective effect of this allele was observed in Caucasians (OR, 0.93; 95% CI, 0.73-1.18; P ¼ 0.54). The fail-safe number at the level of 0.05 was in favour of our findings. Our casecontrol study and the following meta-analysis failed to provide evidence for the genetic association of a-adducin gene G460W polymorphism with hypertension.
Introduction
The past two decades have seen an upsurge in detecting and characterizing the genetic infrastructure of hypertension with a chain of candidates listed as hypertension genes on account of their physiological or biological influence on blood pressure regulation, electrolyte balance or signal transduction. 1, 2 One polymorphism therein ranks high in a-adducin gene, Trp in place of Gly at aminoacid residue 460 (G460W, rs4961), which was first described by Cusi et al. 3 Human a-adducin gene is mapped to chromosome 4p16.3 and comprises 16 exons. Animal models using the Milan hypertensive rat strain suggested that the a-adducin point mutation could affect renal sodium transport and thus explain a large proportion of blood pressure variation. 4, 5 Moreover, in Caucasians, a joint test of linkage and association provided proof for the positive correlation between a-adducin genetic variation and hypertension. 3 Subsequently, a great number of studies seeking to linking the G460W polymorphism to hypertension have been conducted in other races and ethnics, whereas results are often irreproducible. 3, 6, 7 As a caveat, this may reflect difficulties in the replication of supportive findings, such as the heterogeneity of genetic susceptibility and individual studies with low statistical power.
To address this issue fully, expanding our previous work, 8 we first re-evaluated the association of a-adducin gene G460W polymorphism with essential hypertension among Shanghai residents, and then meta-analyzed all available reports of this kind from the English published literature.
Methods
Case-control study Study population. This was a hospital-based casecontrol study including a total of 950 unrelated Han Chinese recruited from the Shanghai area. There were 475 patients diagnosed with essential hypertension and 475 age-, gender-and area-matched healthy controls. The institutional review board of the Ruijin Hospital, Shanghai Jiaotong University School of Medicine approved this study and all subjects gave informed written consent at enrolment.
Demographic measurement. Blood pressure was measured on three occasions with at least 5 min intervals by experienced and certified examiners according to a standard protocol recommended by the American Heart Association and three consecutive values were averaged for analysis. 9 Hypertension was defined as a systolic blood pressure (SBP) exceeding 140 mm Hg or diastolic blood pressure (DBP) exceeding 90 mm Hg or use of anti-hypertensive medication. Clinical and laboratory evaluations were conducted to exclude cases of secondary hypertension. The blood pressure of all the controls was below 140/90 mm Hg and they had no familial hypertension history and were free of diabetes and renal disease. Body weight and height as well as waist and hip measurements were recorded with subjects wearing light indoor clothing and no shoes. Body mass index (BMI) was calculated as weight in kg divided by the square of height in metres. Waist-hip ratio (WHR) was calculated as waist in centimetres divided by hip in centimetres.
Clinical assessment. Fasting plasma glucose was detected by Glucorder analyzer (Roche). Plasma triglyceride, and total, high-and low-density lipoprotein cholesterol as well as blood urea nitrogen, creatinine, uric acid were determined enzymatically using available kits and autoanalyzer at Ruijin Hospital.
Genotyping. Blood samples (5 ml) were drawn and genomic DNA was extracted from white blood cells using the phenol/chloroform method. The genotypes of G460W were determined by the PCR and restriction fragment length polymorphism techniques. In details, the sequence of the forward primer was 5 0 -CGACGAAGCTTCCAAGGA-3 0 and that of the reverse primer was 5 0 -ACAGTAAGGTAGGCAC AGA-3 0 according to a previous report. 10 PCR reaction was carried out in a PTC-200 MJ Research Peltier Thermal Cycler (PerkinElmer, Foster City, CA, USA) and its amplification was performed with 50-100 ng of DNA in a total volume of 20 ml containing 20 pmol of each primer, 500 mmol l À1 dNTPs, 25 mmol l À1 MgCl 2 and 0.5 U Taq DNA polymerase (Fermentas, Shanghai, China). The restriction enzyme PflMI (Promega, Shanghai, China) recognized the amplified fragment (166 bp) when 460W allele was present (148 and 18 bp), but not when 460G allele was present. The digested products were separated on 3.5% agarose gels. To avoid genotyping misclassification, we added a known marker for each PCR or digested product.
Meta-analysis Literature search. The PubMed, EMBASE and Web of Science search engines were used for the electronic publications with the last update on 1 August 2009. Keywords used for the search were 'hypertension' and 'alpha-adducin or a-adducin' combined with 'gene or variant or polymorphism or allele', which were all MeSH (Medical Subject Headings in the US National Library of Medicine) terms. The 'related articles' in the MEDLINE option as well as reference lists of all retrieved studies were checked for other relevant publications that were not identified initially. If there were multiple publications from the same study group, the most complete and recent results were extracted. Search results were limited to articles published in English and studies on humans without country restrictions. To avoid selection bias, we did not reject any study because of poor-quality scores.
Inclusion/exclusion criteria. Case-control studies were included in this meta-analysis regardless of sample size, if they explored the association of a-adducin G460W polymorphism with hypertension among unrelated subjects; if genotyping had been performed by using validated methods and if they provided sufficient information on the genotype or allele frequencies for effect estimate and its corresponding confidence interval (CI). All odds ratios (ORs) were calculated against healthy controls. Hypertension was defined as SBP or DBP X140 or 90 mm Hg or treatment with anti-hypertensive medication.
Data extraction. The following information was extracted from each study: first author's last name, year of publication, ethnicity of the population studied, number of subjects in each category, baseline information of the study population, Meta-analysis was conducted using the Review Manager software (version 5.0; http://www.cc-ims. net/revman/download). Contrasts of G460W alleles or genotypes between cases and controls were expressed in the form of ORs and 95% CIs. The genotype effects were estimated using the modelfree approach, where no assumption about genetic models is required.
The presence of between-studies heterogeneity was calculated using the w 2 -based Cochrane's Q statistic with statistical significance at the level of 0.10 as this statistic is proved to have poor power if there are few studies. 11, 12 Besides, the I 2 statistic was documented for the percentage of the observed between-study variability due to heterogeneity rather than chance with the ranges of 0-100% (I 2 ¼ 0-25%, no heterogeneity; I 2 ¼ 25-50%, moderate heterogeneity; I 2 ¼ 50-75%, large heterogeneity; I 2 ¼ 75-100%, extreme heterogeneity). 12 Using Mantel-Haenszel method, we applied a fixed-effects model in the absence of between-studies heterogeneity, and a random-effects model otherwise. Theoretically, random effects models are more conservative and have a wider CI than fixed effects ones.
Publication bias was assessed by the fail-safe number (N fs ) of each meta-analysis. If the N fs for one polymorphism was smaller than the number of observed studies for that polymorphism, the metaanalysis result of the gene variant might have a significant publication bias. In this study, the N fs significance was established at P ¼ 0.05 (N fs0.05 ¼ (SZ/1.64) 2 -k; k being the number of articles included in each meta-analysis).
Results

Description of our study population
The baseline characteristics of our study population are presented in Table 1 . Patients with essential hypertension and normotensive controls showed a similar age (P ¼ 0.372) and gender (P ¼ 0.559) distribution. The mean values of BMI, waist-hip ratio and blood pressure were significantly higher in cases than in controls (Po0.001), as well as for plasma total cholesterol, triglyceride, low-density lipoprotein cholesterol, blood urea nitrogen, creatinine and uric acid levels (Po0.001). In contrast, plasma high-density lipoprotein cholesterol levels was higher in controls than in cases (Po0.001).
Genetic information on our case-control study The genotype distributions for a-adducin gene G460W polymorphism were in conformity with the Hardy-Weinberg equilibrium in both cases and controls (P40.05). Shown in Table 2 is the genotype/allele distributions of this polymorphism and its three genetic modes of inheritance. Above all, no statistical significance was observed for the genotype (P ¼ 0.617) and allele (P ¼ 0.818) association of G460W polymorphism with essential hypertension, even under assumption of the three genetic modes of inheritance.
Description of studies identified in meta-analysis
The initial search strategy retrieved 91 potentially relevant articles, in which the effect of a-adducin gene polymorphisms on hypertension was examined. A total of 17 studies met selection criteria, whereas only 14 studies 3,6,7,10,13-22 were considered The baseline characteristics for these eligible studies are given in Table 3 . Seven studies were carried out in Caucasians, 3, 7, 15, 16, 18, 19, 21 seven in Asian populations (including this study), 6, 10, 13, 14, 20, 22 one in black South African population 17 and one in mixed populations. 19 The sample sizes ranged from 145 to 2626. Fourteen studies provided information on G460W polymorphism associated with hypertension or essential hypertension, and one with isolated systolic hypertension. 16 For studies with necessary genotype counts, all genotype distributions satisfied Hardy-Weinberg equilibrium for both cases and controls at the significance of 0.05 except one study in cases. 22 The percentage of men ranged from 25.0 to 83.2% for cases and from 23.4 to 59.3% for controls. The mean age ranged from 44.0 to 73.7 years for cases and 42.5 to 71.9 years for controls, and the mean BMI from 23.4 to 31.1 kg m À2 for cases and 21.9 to 32.8 kg m À2 for controls. The frequencies of 460W allele differed widely, especially between Caucasians and Asians. For example, in Caucasians, the frequencies were in the ranges of 14.4-24.4% for cases and 13.0-25.0% for controls, which were remarkably lower than that in Asians, especially in Chinese and Japanese ranging from 54.1 to 65.6% for cases and 52.6 to 60.4% for controls. In contrast, the identification in a South-African population 17 yielded an exceedingly low frequency of 8.1% for cases and 3.2% for controls. Figure 1 shows the pooled analysis of G460W allele association with hypertension. Of 15 studies with 17 populations, 10 individual OR estimates showed a higher or similar risk of hypertension for 460W allele compared with 460G allele, with only 4 earlier studies reaching significance. The other seven populations showed a decrease in hypertension risk for 460W allele, but none of them was statistically significant. The summary OR under a random effects model indicated that carriers of 460W allele were 1.04 time more likely to develop hypertension (95% CI, 0.91-1.18; P ¼ 0.58).
Meta-analysis results
In view of the striking differences in the frequency of 460W allele in Caucasians and Asians, we performed subgroup analyses by race. In Caucasians, we observed a protective effect of 460W allele for hypertension compared with 460G allele (OR, 0.93; 95% CI, 0.73-1.18; P ¼ 0.54), and this effect persisted after excluding a study with mixed populations 19 and another study investigating isolated systolic hypertension. 16 In contrast, after restricting analysis to Asians, we observed a risk effect of 460W allele for hypertension (OR, 1.09; 95% CI, 0.96-1.24; P ¼ 0.19), which was almost similar in magnitude in Japanese or Chinese populations. Because there was only one study performed in Africans, 17 the OR estimate showed a significantly higher risk of 460W allele carriers for hypertension compared with that of 460G allele (OR, 2.68; 95% CI, 1.07-6.68; P ¼ 0.03).
In addition, cumulative analysis of the 460W versus 460G contrast showed the influential role of the first two studies by Cusi et al. 3 and Iwai et al.
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with this effect attenuated by following studies. The overall estimates became insignificant (OR, 1.27; 95% CI, 0.92-1.72; P ¼ 0.14) only after the study by Kato et al. 14 was included in the cumulative metaanalysis, and this trend gradually became smooth (ORs: 1.27, 1.26, 1.32, 1.22, 1.16, 1.09, 1.04, 1.05, 1.05, 1.05, 1.03, 1.04, 1.04; P40.05). After excluding the first two studies, the overall estimate, albeit insignificant, showed a protective effect of 460W allele compared with 460G allele (OR, 0.95; 95% CI, 0.84-1.07; P ¼ 0.40) (data not shown).
Shown in Table 4 is the genotype association of G460W polymorphism with hypertension in the meta-analysis under the random effects models. For all studies, the overall OR estimates showed a-Adducin Gly460Trp polymorphism and hypertension W-Q Niu et al Table 3 The baseline characteristics of all the studies in this meta-analysis After restricting analysis to Caucasians and Asians, respectively, negative association persisted for all contrasts. Moreover, in sensitivity analysis, no appreciable changes were observed for the overall OR estimates of allele/ genotype association for all studies, even upon stratification by race (Caucasians and Asians) (data not shown).
Publication bias
To assess publication bias, we calculated the failsafe number (N fs ) at the level of 0.05 for each contrast. The N fs0.05 values for all the contrasts were greater (range, 52 for 460WW versus 460GG genotype in contrast to 230 for 460W versus 460G allele contrast) than the number of studies included (n ¼ 17 or 15) in the meta-analysis.
Discussion
To the best of our knowledge, this is the first study seeking to investigate the association of a-adducin G460W polymorphism with hypertension. Along with the present case-control study, 15 studies involving 4417 cases and 5716 controls were finally meta-analyzed. Although some statistical bias could not be eliminated, this meta-analysis failed to show overall a statistically significant association of G460W polymorphism with hypertension, even upon stratification by race (Caucasians and Asians). Similarly, this association in our study was negative as well. Previously, we combined the linkage and association strategies to test the correlation of a-adducin G460W polymorphism with essential hypertension, while no positive relations were observed. 8 In view of the small sample size (138 cases and 121 controls) of this study, 8 we here re-visited the evidence supporting or refuting the association of G460W polymorphism with essential hypertension in an enlarged population of Shanghai residents. Unfortunately, we still failed to see any suggestive evidence for this association. In contrast, another study by Ju et al. 6 conducted among northern Chinese showed a positive and independent association of G460W polymorphism with essential hypertension. Except for the differences in dietary salt consumption between northern and southern Chinese as discussed by Ju et al., 6 another possibility is due to the 'healthy worker effect' in Ju et al. study because the study subjects were recruited from the employees of Qingdao Port. It is recognized that working populations tend to be healthier than the general populations, raising the possibility that genetic Figure 1 The contrast of the a-adducin 460W allele versus 460G allele under a random effects model. a-Adducin Gly460Trp polymorphism and hypertension W-Q Niu et al predisposition may differ due to population structure differences. Hypertension is a late onset disorder and the age-dependent genetic effects should not be ignored because risk for hypertension increases as a result of accumulating physiological and biological changes with age. 25 In fact, the mean age in this study was approximately 8 years older than that in the study by Ju et al. To avoid the premature conclusion, we thereby conducted a meta-analysis for all available information regarding the association of G460W polymorphism with hypertension.
After taking all studies together in the metaanalysis, neither allele nor genotype associations reached statistical significance, even in subgroup analyses. Except for the first two studies with positive results, 3, 13 most of the subsequent replications were insignificant. In view of the fact that the fail-safe numbers at the level of 0.05 were all greater than the number of reports studied for all contrasts, it seems unlikely that the present results is due to chance. After taking a fresh look at individual studies in the meta-analysis, it is surprising to notice the wide distributions of 460W allele. For example, the frequency of 460W allele in Asians (52.6-60.4%) was more than double than that in Caucasians (14.4-24.4%). As suggested by a recent data-mining study, differences in allele frequency can result in a reversal of allelic effects where a protective allele becomes a risk factor in replication studies. 26 As expected, the roles of 460W allele, albeit insignificant, were totally divergent between Caucasians and Asians, which leads to the speculation that if involved, the G460W polymorphism may have pleiotropic effects on the aetiology of hypertension among different races or ethnic groups. Moreover, we cannot preclude the possibility that the G460W polymorphism may not, by itself, exhibit significant association with hypertension in all or most studies because its effect may be small and dependant on genotypes at other loci that compensate for variation in the locus under study. 27 In this situation, a parsimonious subset of tag polymorphisms will be reliable to predict and further detect the underlying common genetic variation of hypertension surrounding G460W polymorphism. Furthermore, failure to replicate an independent genetic effect may provide important clues about the complexity of the underlying genetic architecture such as gene-gene and gene-environment interactions. 26 As analysis of single polymorphisms can be misleading, persuasive evidence suggests that a mosaic network with a lot of genetic and environmental factors interacting with each other is necessary to clarify this uncertainty comprehensively. 27, 28 Thus, considering the complex pathogenesis of hypertension, more studies are warranted to confirm or refute our findings.
The present meta-analysis should be interpreted within the context of its limitations. First, for the case-control design of all included studies, this meta-analysis inevitably has the weaknesses expected from this type of study, such as the inability to prove the existence of a causal relationship. Second, in this case-control study as well as the following meta-analysis, we only focused on hypertension as a categorical trait rather than the continuous blood pressure form, which runs the risk of losing some information. Third, we cannot retrieve information upon various confounding factors, such as smoking, salt consumption, from all these original publications, which are regarded as effective modulators for the development of hypertension. Fourth, in this study, we only metaanalyzed the association of a-adducin gene G460W polymorphism with hypertension, and did not evaluate other polymorphisms in this gene and other targeted genes that might be associated with hypertension such as b-adducin gene. It is possible that the potential role of G460W polymorphism is diluted or masked by other gene-gene or geneenvironment interactions if considered.
Taken together, our case-control study and the following meta-analysis failed to provide evidence for the genetic association of a-adducin G460W polymorphism with hypertension, even upon stratification by race. Further studies with welldesigned genetic interaction and functional validation are warranted.
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